Astellas’ Xtandi (enzalutamide) Receives NMPA’s Approval for Metastatic Castration-Resistant Prostate Cancer in Men

 Astellas’ Xtandi (enzalutamide) Receives NMPA’s Approval for Metastatic Castration-Resistant Prostate Cancer in Men

Astellas’ Xospata (gilteritinib) Receives FDA ‘s Approval for 1L R/R Acute Myeloid Leukemia (AML) in Adults

Shots:

  • The approval is based on P-III Asian PREVAIL study assessing Xtandi (160mg/day) vs PBO + GnRH therapy or after bilateral orchiectomy in patients with progressive metastatic mCRPC who had disease progression despite ADT and a single dose PK study in 200 Chinese patients
  • The P-III Asian PREVAIL study results: reduction in risk of PSA progression; median time to PSA progression (8.31 vs 2.86mos.); reduction in radiographic disease progression; improvement in OS; 67% reduction in the risk of death
  • Xtandi is a nonsteroidal antiandrogen medication, indicated for use in conjunction with castration in the treatment of metastatic castration-resistant prostate cancer and nonmetastatic castration-resistant prostate cancer

Click here to­ read full press release/ article | Ref: Astellas | Image: Behance

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post